Orexo AB (publ) said that its partner Mundipharma GmbH has launched opioid dependence treatment Zubsolv in the EU, triggering a milestone payment of €3 million from Mundipharma.

Germany-based Mundipharma gained the rights to Zubsolv outside the U.S. in a June 2016 agreement with the Swedish drugmaker.

The treatment is in the form of a tablet, containing buprenorphine and naloxone, that is placed under the tongue.

Recently, Mylan NV and Dr. Reddy's Laboratories Ltd. gained the U.S. Food and Drug Administration's approval to market generic versions of Indivior PLC's Suboxone film, also a combination of buprenorphine and naloxone.